Nasal spray could tame tough asthma Flare-Ups
Disease control
Not yet recruiting
This Phase 2 trial tests AD17002, a nasal spray that aims to calm the immune system in people with moderate to severe eosinophilic asthma that is not well controlled by current treatments. About 126 adults will receive either the spray or a placebo for 3 months. Researchers will …
Phase: PHASE2 • Sponsor: Advagene Biopharma Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC